RGN-259

胸腺肽β4

Report date: 2026/03/09 20:02:04
NME

Base Information

Drug NameRGN-259
Drug Alias NameTimbetasin (RegeneRx Biopharmaceuticals)Thymosin beta-4 (RegeneRx Biopharmaceuticals)Thymosin beta 4-16-38Thymosin beta4Thymosin B4 +[15] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionActin modulatorsAmyloid inhibitorsAngiogenesis inducers +[11] 
TargetsActinAmyloidCollagen +[7] 
Therapy Area/IndicationsGraft vs Host DiseaseDiabetes MellitusPressure Ulcer +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNational Institutes Of Health
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesLee'S Pharmaceutical (Hk) LtdRegentree Llc
Inactive CompaniesMichigan Cornea Consultants PcRegenerx Biopharmaceuticals IncLenus Therapeutics Llc +[4] 
Active IndicationsDry Eye SyndromesKeratitisXerophthalmia
Inactive IndicationsGraft vs Host DiseaseDiabetes MellitusPressure Ulcer +[11] 

Other Information

ATC CodeN/A
Related LinksWikipedia